FDA approves Botox to treat overactive bladder
Jan 18 (Reuters) - U.S. health regulators approved Allergan Inc's blockbuster wrinkle smoother Botox to treat adults with overactive bladders who do not respond adequately to other therapies.
The U.S. Food and Drug Administration said Botox can be injected into the bladder muscle, allowing the muscle to relax and improving bladder capacity.
The treatment can be repeated when the effect wears off, but with a gap of at least 12 weeks between treatments, the FDA said in a statement on its website. ()
- Obama unveils U.S. immigration reform, setting up fight with Republicans |
- More arrests as protesters await Ferguson grand jury decision
- 'Immoral, but not illegal': metal warehousing games in the spotlight
- Exclusive: U.S. increasing non-lethal military aid to Ukraine
- Western leaders step away from nuclear talks with Iran as deadline nears